QURE Jan 2025 8.000 call
| Previous Close | 0.3700 |
| Open | 0.4000 |
| Bid | 0.2500 |
| Ask | 0.4500 |
| Strike | 8.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.3700 - 0.4000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2.47k |
GlobeNewswireuniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AMT-191, uniQure’s investigational gene therapy for the treatment of Fabry disease, a rare, inherited genetic disease. In August 2024, uniQure announced the dosing of the first patient in its U.
Simply Wall St.uniQure (NASDAQ:QURE) investors are sitting on a loss of 88% if they invested five years ago
While it may not be enough for some shareholders, we think it is good to see the uniQure N.V. ( NASDAQ:QURE ) share...
- GlobeNewswire
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in a Phase I/IIa clinical trial of AMT-191 for the treatment of Fabry disease, a rare, inherited genetic disease. The Phase I/IIa study is a multi-center, open-label trial being conducted in the United States with two dose-escalating cohorts ass
